Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioblastoma 1Astrocytoma 1

Interventions

Specimen Handling 439Magnetic Resonance Spectroscopy 341pembrolizumab 288Biopsy 241Carboplatin 230Cisplatin 193Cyclophosphamide 185Paclitaxel 164Nivolumab 153Gemcitabine 151Bevacizumab 121Radiotherapy 119Dexamethasone 113fludarabine 99Pemetrexed 99Fluorouracil 94durvalumab 90Doxorubicin 90venetoclax 89Docetaxel 89Radiation 88Oxaliplatin 88Rituximab 87atezolizumab 84Leucovorin 79Capecitabine 75Prednisone 74Lenalidomide 69Etoposide 69X-Rays 65

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × vocimagene amiretrorepvec × 30 days × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡